Physician profile
Boyu Hu
NPI 1033478144
$280,895.25
in general payments reported to CMS, 2019-2025
21 companies · $234K in 2025
The $234K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.10 · 2022: $17K · 2023: $12K · 2024: $18K · 2025: $234K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $225K · Consulting Fee: $33K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,160 · Food and Beverage: $1,647 · Travel and Lodging: $1,178 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $454 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $225,000.00 |
| Consulting Fee | $33,180.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,160.00 |
| Food and Beverage | $1,646.55 |
| Travel and Lodging | $1,178.15 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $453.74 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $225,000.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $9,576.68 | 2022-2025 | |
| Regeneron Pharmaceuticals, INC. | $8,789.17 | 2023-2024 | |
| Adc Therapeutics America, INC. | $7,016.04 | 2022-2025 | |
| Beigene USA, INC. | $4,703.72 | 2023-2025 | Brukinsa |
| Eli Lilly and Company | $4,375.00 | 2022 | |
| Seagen INC. | $4,372.39 | 2022-2023 | Adcetris |
| Novartis Pharmaceuticals Corporation | $4,324.07 | 2022 | |
| Genentech USA, INC. | $3,470.21 | 2019-2025 | Lunsumio, Polivy, Columvi |
| Beone Medicines USA, INC. | $2,923.67 | 2025 | Brukinsa |
| Pfizer INC. | $2,336.78 | 2024-2025 | |
| Kite Pharma, INC. | $2,080.00 | 2024 | Yescarta |
| Abbvie INC. | $757.25 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $657.83 | 2024-2025 | Enhertu |
| Taiho Oncology, INC. | $276.49 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $155.00 | 2022 | |
| Argenx US, INC. | $58.60 | 2024 | Vyvgart |
| Lilly USA, LLC | $22.35 | 2024 | Jaypirca |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boyu Hu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.